Patent · US Active

Antibodies to modified human IGF-1/E peptides

US8753632B2 · kind B2 · utility

0Cited by

2References

3Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Mara Fornaro · Basel, CH
John Liuzhong Xu · Shanghai, CN
Yuan Gao · San Diego, US
Rainer Hillenbrand · Königsbrunn, DE
Francois Legay · Rixheim, FR
Daniela Stoellner · Basel, CH

Key dates

Filing date	Nov 10, 2009
Grant date	Jun 17, 2014
Priority date	—
Expiry date	Oct 23, 2030

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/65
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.